HIV-1 VprB and C RNA cleavage by potent 10-23 DNAzymes that also cause reversal of G2 cell cycle arrest mediated by Vpr genes

Oligonucleotides

Volumn 17, Issue 4, 2007, Pages 465-472

  Bano, Aalia S ^a   Gupta, Nidhi ^a   Sharma, Yogeshwar ^a   Sood, Vikas ^a   Banerjea, Akhil C ^a,b  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^b JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYRIBOZYME; DNA; PROTEIN VPRB; PROTEIN VPRC; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA; VPR PROTEIN;

ARTICLE; CATALYSIS; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL FUNCTION; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOPATHOLOGY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME STRUCTURE; GENE SEQUENCE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INDIAN; MAMMAL CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOLOGY; PRIORITY JOURNAL; RNA CLEAVAGE; RNA STRUCTURE; VIRUS GENE; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS STRAIN; VPR GENE; VPRB GENE; VPRC GENE;

BASE SEQUENCE; CELL LINE; DNA, CATALYTIC; G2 PHASE; GENE PRODUCTS, VPR; GENES, VPR; HELA CELLS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL;

HUMAN IMMUNODEFICIENCY VIRUS 1; MAMMALIA;

EID: 37549044256     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2007.0091     Document Type: Article

References (20)

1. ADACHI, A., GLENDELMAN, H.E., KOENIG, S., FOLKS, T., WILLEY, R., RABSOM, A., and MARTIN, M. (1986). Production of acquired immunodeficiency syndrome associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59, 284-291.
2. AKKINA, R., BANERJEA, A., BAI, J., ANDERSON, J., LI, M.J., and ROSSI, J. (2003). siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS. Anticancer Res. 23, 1997-2005.
3. BANERJEA, A.C., CHAKRABORTI, S., UNWALLA, H., GOILA, R., SHRABANI, B., DASH, B.C., SRIRAM, B., PARAMASIVAM, N., and VISWANATHAN, S. (2005). Potential therapeutic application of DNA enzymes and siRNAs against viral and cellular genes. In: Synthetic Nucleic Acids as Inhibitors of Gene Expression: Mechanisms, Applications, and Therapeutic Implications. L.M. Khachigian, ed. (CRC Press, Boca Raton, FL), pp. 115-134.
4. BANO, A.S., GUPTA, N., SOOD, V., and BANERJEA, A.C. (2007). Vpr from HIV-1 subtype B and C exhibit significant differences in their ability to transactivate LTR-mediated gene expression and also in their ability to promote apoptotic DNA ladder formation. AIDS, in press.
5. CHAKRABORTI, S., and BANERJEA, A.C. (2003a). Identification of cleavage sites in the HIV-1 TAR RNA by 10-23 and 8-17 catalytic motif containing DNA-enzymes Biomacromolecules 4, 568-571.
6. CHAKRABORTI, S., and BANERJEA, A.C. (2003b). Inhibition of HIV-1 replication by 10-23 catalytic motif containing DNA-enzymes targeted against HIV-1 TAR element: potential effectiveness against all HIV-1 isolates. Mol. Ther. 7, 817-826.
7. GIBBS, J.S., LACKNER, A.A., LANG, S.M., SIMON, M.A., SEHGAL, P.K., DANIEL, M.D., and DESROSIERS, R.C. (1995). Progression to AIDS in the absence of a gene for Vpr or Vpx. J. Virol. 69, 2378-2383.
8. GOH, W.C., ROGEL, M.E., KINSEY, C.M., MICHAEL, S.F., FULTZ, P.N., NOWAK, M.A., HAHN, B.H., and EMERMAN, M. (1998). HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat. Med. 4, 65-71.
9. GOILA, R., and BANERJEA, A.C. (2001). Inhibition of hepatitis B virus X gene expression by novel DNA enzymes. Biochemical J. 353, 701-708.
10. HIRSCH, V.M., SHARKEY, M.E., BROWN,C.R., BRICHACEK,B., GOLDSTEIN, S., WAKEFIELD, J., BYRUM, R., ELKINS, W.R., HAHN, B.H., LIFSON, J.D., and STEVENSON, M. (1998). Vpx is required for dissemination and pathogenesis of SIV (SM): evidence of macrophage-dependent viral amplification. Nat. Med. 4, 1401-1408.
11. JIAN, H., and ZHAO, L.J. (2003). Pro-apoptotic activity of HIV-1 auxillary regulatory protein Vpr is subtype-dependent and potentially enhanced by nonconservative changes of the leucine residue at position 64. J. Biol. Chem. 278, 44326-44330.
12. JOYCE, G.F. (2004) Directed evolution of nucleic acid enzymes. Annu. Rev. Biochem. 73, 791-836.
13. KURRECK, J., BIEBER, B., JAHNEL, R., and ERDMANN, V.A. (2002). Comparative study of DNA enzymes and ribozymes against the same full-length messenger RNA of the Vanilloid receptor subtype 1. J. Biol. Chem. 277, 7099-7107.
14. LUMM, J.J., COHEN, O.J., NIE, Z., WEAVER, J.G., GOMEZ, T.S., YAO, X.J., LYNCH, D., PILON, A.A., HAWLEY, N, KIM, J.E., et. al. (2003). Vpr R77Q is associated with long term nonprogressive HIV infection and impaired induction of apoptosis. J. Clin. Invest. 111, 1547-1554.
15. ROUSSEAU, C.M., LEARN, G.H., BHATTACHARYA, T., NICKLE, D.C., HECKERMAN, D., CHETTY, C., BRANDER, C., GOULDER, P.J.R., WALKER, B.D., KIEPIELA, P., KORBER, B.T., and MULLINS, J.I. (2007). Extensive intrasubtype recombination in South African human immunodeficiency virus type 1 subtype C infections. J. Virol. 81, 4492-4500.
16. ROUZIC, E.L., and BENICHOU, S. (2005). The Vpr protein from HIV-1: distinct roles along the viral life cycle. Retrovirology 2, 11.
17. SAKAI, S., DIMAS, J., and LENARDO, J.M. (2006). The Vif and Vpr accessory proteins independently cause HIV-1 induced T cell cytopathocity and cell cycle arrest. Proc. Natl. Acad. Sci. USA 103, 3369-3374.
18. SANTORO, S.W., and JOYCE, G.F. (1997). General purpose RNA-cleaving DNA enzyme. Proc. Natl. Acad. Sci. USA 94, 4262-4266.
19. SCHUBERT, S., and KURRECK, J. (2006). Oligonucleotide-based antiviral strategies. Handb. Exp. Pharmacol. 173, 261-287.
20. SILVERMAN, S.K. (2005). In vitro selection, characterization, and application of deoxyribozymes that cleave RNA. Nucleic Acids Res. 33, 6151-6163.